For young patients with the kidney disease IgA nephropathy, early treatment with angiotensin-converting enzyme inhibitors can reduce the long-term risk of irreversible kidney damage, suggests a study in the June Journal of the American Society of Nephrology.
Treatment with the drug clodronate does not improve overall survival for men with localized prostate cancer or delay the disease?s progression to metastatic cancer, according to the results of a randomized clinical trial.
Scientists have shown that a single 2.5mg dose of vitamin D may be enough to boost the immune system to fight against tuberculosis (TB) and similar bacteria for at least 6 weeks.
Postmenopausal women who take calcium and vitamin D supplements may gain less weight than those who do not, although the overall effect is small, according to a report in the May 14 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.
A Mayo Clinic research team led by neurologist David Knopman, M.D. will join a nationwide consortium of leading Alzheimer’s disease researchers in a large-scale clinical trial evaluating the effectiveness of omega-3 fatty acids in slowing the progression of Alzheimer’s disease.
Biogen Idec (NASDAQ: BIIB) and Vernalis plc (LSE: VER, Nasdaq: VNLS) announced the initiation of the Phase II program of BIIB014 (also known as V2006), an oral compound, for the treatment of Parkinson’s disease.
The U.S. Food and Drug Administration (FDA) announced the approval of Neupro (rotigotine transdermal system), a skin patch designed to treat symptoms of early Parkinson’s disease.
Nutritionists have long endorsed fish as part of a heart-healthy diet, and now some studies suggest that omega-3 fatty acids found in the oil of certain fish may also benefit the brain by lowering the risk of Alzheimer’s disease.
While many migraine sufferers experience traditional symptoms such as nausea or sensitivity to light and sound, migraine attacks can also involve symptoms like neck pain or sinus pain that are not traditionally associated with migraine headaches.
Data from two clinical trials presented at the American Academy of Neurology (AAN) meeting suggest that an investigational once daily extended re-lease formulation of Lamictal? (lamotrigine) is effective as add-on treatment in patients with partial epilepsy with and without secondary generalization. Lamictal XR Extended-Release Tablets are currently in development for the treatment of epilepsy. If approved, it will be the first extended release, new generation epilepsy treatment taken once-daily.